FINWIRES · TerminalLIVE
FINWIRES

Wedbush称，Pegasystems借助Blueprint平台有望加速增长。

By

-- Wedbush Securities周五发布的一份报告称，随着Pegasystems (PEGA)的低代码工作流设计平台Blueprint在早期客户互动中发挥越来越重要的作用，该公司有望加速年度合同价值增长，并实现其2026年自由现金流目标。 Wedbush表示，在与Pegasystems高管进行讨论后，该公司“更加看好”该公司，并认为近期股价的回调“反应过度”。 Wedbush指出，Blueprint通过帮助潜在客户在初次会面时设计和可视化用例，简化了Pegasystems与潜在客户的合作方式，而这在过去一直是该公司成本高昂的环节。报告称，该平台的易用性支撑了人们的预期，即新客户将在2026财年推动订阅合同增长约15%，高于此前预测的10%。 Wedbush指出，在成本控制方面，Pegasystems对股权激励采取了“有条不紊的方法”，将其控制在营收的8%至9%之间，并优先考虑薪酬的稳定性，而非将其与波动的股价挂钩。报告称，这种严谨的管理方式应有助于公司在面临更广泛的软件行业压力时，依然能够持续产生自由现金流。 Wedbush维持对Pegasystems股票的“跑赢大盘”评级，目标价为60美元。

Price: $36.53, Change: $-0.02, Percent Change: -0.05%

Related Articles

Mining & Metals

Update: WTI Oil Falls As Iran Offers New Peace Plan

West Texas Intermediate (WTI) crude oil closed lower Friday as Iran made a new peace proposal, however U.S. President Trump rejected the plan.WTI crude oil for June delivery closed down US$3.13 to US$101.94 per barrel, while July Brent oil was last seen down US$2.177 to US$108.23.Reuters reported Iran offered a new proposal to reach a peace deal with the United States. While details were not disclosed Trump rejected the plan, telling reporters he was not satisfied with the plan. However he confirmed indirect talks mediated by Pakistan are continuing by phone.Oil remains in short supply following the closure of the Strait, the chokepoint for exports from the Persian Gulf nations that accounted for 20% of daily demand. The lack of supply has pushed up crude oil prices by more than half since the Feb.28 start of the war amid shortages of crude oil and refined products, with Nymex gasoline futures up 81% since the war began while supplies of aviation are tightening.The supply crunch comes ahead of the May 23 start to the Memorial Day weekend, the traditional start of the summer driving season, when demand for fuel peaks, which is likely to push prices even higher."With summer demand season quickly approaching, we see a path for oil prices to exceed the 2022 and even 2008 highs, especially as sentiment may finally be shifting on the duration of the Hormuz blockage," Helima Croft, Head of Global Commodity Strategy and MENA Research at RBC Capital Markets, wrote.

$CLM6$LCON6$USO
Mining & Metals

CIBC Raises Its Primaris REIT Price Target By C$2, Reiterates its Outperformer Rating

CIBC Capital Markets reiterated its outperformer rating on the shares of Primaris Real Estate Investment Trust (PMZ-UN.TO) while raising its price target to C$22.00 from C$20.00 on Thursday, following PMZ's first quarter results on Wednesday.PMZ reported Q1 FFO/unit of $0.425 (-3.2% Y/Y), broadly in line with consensus, noted CIBC."Our 2027 FFO/unit estimate rises by near 2%, as we better reflect the improved leasing cadence on the ground," said CIBC, adding it $22 price target is based on an 11 times 2027 estimated FFO/unit multiple (10.2 times previously), translating to a 5% discount to the bank's revised one-year-out NAV (9% previously), "reflective of its risk, growth prospects, and leverage versus peers."CIBC also reiterated its belief that PMZ unitholders will benefit from occupancy improvements and rent growth over the long term. Tenant relationships for mall operators matter given the reach of their typically national tenant base, CIBC said. Controlling increasingly more productive assets through acquisition and organic growth will increase PMZ's importance to these national tenants, the bank added."PMZ's ability to fund its capex and distribution from its own rents and low balance sheet leverage drive a lower financial risk profile that offsets the risk of owning a higher-risk asset class in enclosed malls," added CIBC. Trading at an implied cap rate of near 8.7% on achievable forecasts, CIBC believes investors are being well compensated for the operating risks involved with owning PMZ units (e.g., anchor tenant transitions) versus the balance of the large-cap Canadian retail REIT universe (trading at estimated implied cap rates of 5.8%-7.1%)."CIBC noted on the call that Primaris will provide a detailed update on its HBC progress in the next 60 days, once it has a significant number of fully executed leases in place, and also that CRU leasing momentum "accelerated meaningfully" in Q1, with management highlighting record new deal volumes and pricing.Price: $19.01, Change: $+0.14, Percent Change: +0.74%

$PMZ-UN.TO
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Bristol-myers Squibb Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $73 from $69, 11.7x our 2027 EPS estimate, a discount to BMY's 10-year historical forward P/E average. We lift our 2026 EPS estimate to $6.30 from $6.22 and maintain our 2027 EPS forecast at $6.18. BMY announced Q1 revenues of $11.5B, a 1% Y/Y increase, and non-GAAP EPS of $1.58, above expectations. The company's growth portfolio, which includes key products such as Reblozyl, Breyanzi, Opdualag, Qvantig, and Cobenfy, and is a key area of focus, saw a 9% Y/Y increase in sales, driven by strong demand for BMY's newer medicines. The quarter was also marked by significant progress in the company's pipeline, with positive data for its CELMoD program and advancements in several late-stage assets. We think the company is successfully navigating a period of important transition, with strong performance from its growth portfolio offsetting declines in legacy products, as we anticipate a series of crucial clinical trial readouts later in the year.

$BMY